NEW YORK, October 13, 2016 /PRNewswire/ --
Stock-Callers.com has taken notice of four Healthcare equities, namely: Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Perrigo Co. PLC (NYSE: PRGO), and Second Sight Medical Products Inc. (NASDAQ: EYES). According to FactSet, the sector is expected to report a 7% revenue growth and a 4% earnings growth in Q3 - the second highest revenue and earnings growth out of the eleven sectors of the S&P 500. Download the free research reports on these stocks today:
Abbott Park, Illinois headquartered Abbott Laboratories' stock finished Wednesday's session 0.44% lower at $40.98, with a total trading volume of 6.40 million shares. The Company's shares have advanced 0.84% in the past month. The stock is trading 0.79% above its 200-day moving average. Additionally, shares of Abbott Laboratories, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 38.67.
On October 12th, 2016, Celgene Corporation and Agios Pharmaceuticals, Inc. announced that each company has entered into collaboration agreements with Abbott Laboratories, to develop and commercialize companion diagnostic tests on Abbott's m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients. See our free and comprehensive research report on ABT at:
On Wednesday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. recorded a trading volume of 10.65 million shares, which was above their three months average volume of 7.80 million shares. The stock ended the session 0.09% higher at $23.18. The Company's shares have advanced 25.70% on an YTD basis. The stock is trading 9.82% above its 200-day moving average. Moreover, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 42.56.
On October 7th, 2016, Boston Scientific announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of EndoChoice Holdings, Inc. at a price of $8.00 per share net to the holder in cash. On September 27th, 2016, the parties announced that they had signed a definitive merger agreement and that the tender offer would follow. EndoChoice's board of directors unanimously approved the terms of the merger agreement, including the tender offer, and recommended that EndoChoice's shareholders tender their shares in the offer. Under the terms of, and subject to the conditions set forth in, the merger agreement, as soon as practicable following the acceptance of shares in the tender offer, Falcon Merger Corp. will merge with and into EndoChoice. All issued and outstanding shares of EndoChoice common stock, other than shares purchased in the tender offer, or shares held by shareholders of EndoChoice who have validly exercised appraisal rights under Delaware law, will be cancelled and converted into the right to receive $8.00 per share, net to the holder in cash, in the merger. BSX free research report PDF is just a click away at:
Shares in Dublin, Ireland headquartered Perrigo Co. PLC closed the day 1.38% lower at $88.00. The stock recorded a trading volume of 2.35 million shares, which was higher than its three months average volume of 2.16 million shares. The Company's shares are trading 4.36% below their 50-day moving average. Additionally, shares of Perrigo, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide, have an RSI of 39.64.
On September 27th, 2016, Perrigo announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine blocking technology and the distribution rights of Zephrex-D® (pseudoephedrine HCI 30 mg). Zephrex-D® was developed using the Tarex® technology and has been proven to be more than 98% effective at blocking one of the more common domestic methods of illegal meth production. Perrigo plans to integrate the Tarex® technology into certain of its store brand and retailer own label pseudoephedrine HCI products in the future and will immediately begin distribution of Zephrex D® to its retail customers. Sign up for your complimentary report on PRGO at:
Second Sight Medical
At the close, shares in Sylmar, California headquartered Second Sight Medical Products Inc. ended the day at $3.03, which was a decline of 2.26%. The stock recorded a trading volume of 329,355 shares, which was higher than its three months average volume of 271,090 shares. The Company's shares are trading below their 50-day moving average by 13.39%. Furthermore, shares of Second Sight Medical Products, which develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the US, Canada, Italy, France, Germany, Saudi Arabia, and the Netherlands, have an RSI of 34.32. Register for free on Stock-Callers.com and download the latest research report on EYES at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA